The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes

February 2019 | Volume 18 | Issue 2 | Supplement Individual Articles | 100 | Copyright © February 2019

James Q. Del Rosso DO,Ma Leon Kircik MD,b Joshua Zeichner MD,c Linda Stein Gold MDd

aJDR Dermatology Research/Thomas Dermatology, Las Vegas, NV; Touro University, Henderson, NV bIcahn School of Medicine at Mount Sinai, New York, NY cIcahn School of Medicine at Mount Sinai, New York, NY dHenry Ford Hospital, Detroit, MI

Figure6Figure7ing, burning, exfoliation, and itching occurred over a range of 1% to 7% in TazF-treated subjects compared to up to 1% in vehicle-treated subjects; similar tolerability outcomes were shown in both genders and across all age groups and races among enrolled subjects. Importantly, study discontinuation occurred in only 2.7% of TazF-treated subjects compared to 0.13% of vehicle-treated subjects. No systemic safety signals were noted.33 Patient Assessments of Characteristics of Aqueous Foam Formulations Subjects in both the two CalcipF phase III studies (n=655) and two TazF phase III studies (n=1396) rated the qualities of their rerespective aqueous foam formulations.41 The results demonstrate that most subjects were highly satisfied with several delivery qualities of both foam vehicles. Figure 6 and Figure 7 show patient survey results of delivery qualities with the calcipotriene aqueous emulsion foam and the tazarotene aqueous foam, respectively. Subjects in both studies who completed these surveys did not know if they were using the active foam or the vehicle foam due to the double-blind methodology used in these pivotal studies.41 The sum effect of these favorable foam delivery characteristics is likely to be improved adherence with treatment among many patients.